Primary Endpoint Results of SYNERGY, a Randomized Phase II Trial, First-Line Chemo-Immunotherapy Trial of Durvalumab, Paclitaxel, and Carboplatin With or Without the Anti-CD73 Antibody Oleclumab

The SYNERGY trial tested first-line chemoimmunotherapy of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer. Although adding oleclumab to durvalumab with chemoimmunotherapy did not increase the clinical benefit rate at week 24, research is ongoing to better understand the mechanisms of response and resistance to this study combination.